| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 34 | 2017 | 860 | 2.940 |
Why?
|
| Glomerulonephritis | 7 | 2018 | 76 | 2.350 |
Why?
|
| Kidney Glomerulus | 8 | 2018 | 122 | 2.000 |
Why?
|
| Skin Neoplasms | 12 | 2018 | 600 | 1.750 |
Why?
|
| Kidney | 19 | 2017 | 1150 | 1.650 |
Why?
|
| Biopsy | 24 | 2021 | 1191 | 1.360 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 8 | 2012 | 36 | 1.320 |
Why?
|
| Graft Rejection | 17 | 2012 | 1081 | 1.300 |
Why?
|
| Capillaries | 8 | 2014 | 90 | 1.200 |
Why?
|
| Acute Kidney Injury | 7 | 2018 | 319 | 1.090 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2015 | 8 | 0.970 |
Why?
|
| Kidney Diseases | 10 | 2017 | 321 | 0.870 |
Why?
|
| Complement C4b | 4 | 2012 | 33 | 0.860 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 4 | 2015 | 21 | 0.850 |
Why?
|
| Glomerulonephritis, Membranous | 3 | 2014 | 23 | 0.840 |
Why?
|
| Dysplastic Nevus Syndrome | 3 | 2018 | 9 | 0.820 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 203 | 0.770 |
Why?
|
| Peptide Fragments | 4 | 2012 | 464 | 0.740 |
Why?
|
| Dermal Fillers | 1 | 2021 | 4 | 0.740 |
Why?
|
| Viscosupplements | 1 | 2021 | 5 | 0.740 |
Why?
|
| Hyaluronic Acid | 1 | 2021 | 52 | 0.710 |
Why?
|
| Polyomavirus Infections | 7 | 2017 | 29 | 0.700 |
Why?
|
| Photomicrography | 1 | 2019 | 7 | 0.690 |
Why?
|
| Nephrotic Syndrome | 3 | 2018 | 33 | 0.680 |
Why?
|
| Nevus, Pigmented | 3 | 2018 | 53 | 0.670 |
Why?
|
| Immunosuppressive Agents | 13 | 2015 | 984 | 0.660 |
Why?
|
| Dermatology | 1 | 2019 | 40 | 0.650 |
Why?
|
| Transplantation, Homologous | 14 | 2014 | 1001 | 0.640 |
Why?
|
| Tumor Virus Infections | 6 | 2017 | 83 | 0.620 |
Why?
|
| Margins of Excision | 1 | 2018 | 42 | 0.600 |
Why?
|
| Kidney Tubules | 3 | 2014 | 92 | 0.590 |
Why?
|
| Skin Diseases | 1 | 2019 | 174 | 0.590 |
Why?
|
| Graft Survival | 8 | 2010 | 910 | 0.590 |
Why?
|
| Renal Dialysis | 2 | 2018 | 338 | 0.580 |
Why?
|
| Nephritis, Interstitial | 6 | 2005 | 44 | 0.570 |
Why?
|
| Female | 54 | 2021 | 46802 | 0.570 |
Why?
|
| Male | 55 | 2021 | 42882 | 0.540 |
Why?
|
| Amyloidosis | 1 | 2018 | 130 | 0.530 |
Why?
|
| Polyomavirus | 2 | 2006 | 16 | 0.530 |
Why?
|
| Adult | 39 | 2021 | 26916 | 0.520 |
Why?
|
| Humans | 77 | 2021 | 90422 | 0.520 |
Why?
|
| Middle Aged | 38 | 2021 | 26295 | 0.500 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 55 | 0.500 |
Why?
|
| Blood Platelets | 2 | 2008 | 151 | 0.490 |
Why?
|
| Immunohistochemistry | 13 | 2018 | 1805 | 0.480 |
Why?
|
| Muscle Neoplasms | 2 | 2013 | 17 | 0.480 |
Why?
|
| Chemotaxis | 1 | 2014 | 73 | 0.470 |
Why?
|
| Hemolysis | 1 | 2014 | 64 | 0.470 |
Why?
|
| Lupus Nephritis | 3 | 2012 | 77 | 0.460 |
Why?
|
| Terminology as Topic | 1 | 2015 | 222 | 0.450 |
Why?
|
| BK Virus | 6 | 2017 | 24 | 0.450 |
Why?
|
| Hemoglobins | 1 | 2014 | 195 | 0.450 |
Why?
|
| Nevus, Blue | 1 | 2013 | 5 | 0.440 |
Why?
|
| Melanocytes | 2 | 2013 | 57 | 0.440 |
Why?
|
| Hamartoma | 1 | 2013 | 35 | 0.430 |
Why?
|
| Retrospective Studies | 15 | 2021 | 9307 | 0.430 |
Why?
|
| Fox-Fordyce Disease | 1 | 2012 | 2 | 0.420 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 272 | 0.410 |
Why?
|
| Aged | 22 | 2021 | 19371 | 0.400 |
Why?
|
| Melanoma, Amelanotic | 1 | 2011 | 1 | 0.390 |
Why?
|
| Chromoblastomycosis | 1 | 2011 | 3 | 0.390 |
Why?
|
| Internship and Residency | 2 | 2019 | 1066 | 0.380 |
Why?
|
| Macrophages | 2 | 2014 | 584 | 0.380 |
Why?
|
| Plasma Cells | 5 | 2012 | 85 | 0.370 |
Why?
|
| Sickle Cell Trait | 1 | 2011 | 21 | 0.360 |
Why?
|
| Respiratory Paralysis | 1 | 2010 | 8 | 0.360 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 417 | 0.360 |
Why?
|
| Renal Artery | 1 | 2011 | 52 | 0.360 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2010 | 21 | 0.360 |
Why?
|
| Integrin beta3 | 2 | 2008 | 32 | 0.350 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2012 | 211 | 0.350 |
Why?
|
| Spinal Cord Injuries | 1 | 2010 | 64 | 0.340 |
Why?
|
| Vascular Diseases | 1 | 2011 | 120 | 0.340 |
Why?
|
| Glomerular Mesangium | 2 | 2018 | 18 | 0.340 |
Why?
|
| Facial Dermatoses | 4 | 2011 | 13 | 0.330 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2008 | 14 | 0.310 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.300 |
Why?
|
| Skin | 4 | 2021 | 590 | 0.290 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 361 | 0.290 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 53 | 0.290 |
Why?
|
| Granuloma | 2 | 2012 | 64 | 0.280 |
Why?
|
| Time Factors | 9 | 2018 | 5361 | 0.280 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2006 | 15 | 0.270 |
Why?
|
| Microscopy | 2 | 2019 | 87 | 0.270 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6802 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1284 | 0.260 |
Why?
|
| Scalp Dermatoses | 3 | 2011 | 10 | 0.250 |
Why?
|
| Proteinuria | 3 | 2004 | 68 | 0.250 |
Why?
|
| Biomarkers | 5 | 2015 | 1795 | 0.250 |
Why?
|
| Adolescent | 12 | 2016 | 9336 | 0.250 |
Why?
|
| Child | 11 | 2016 | 7211 | 0.240 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 644 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1061 | 0.230 |
Why?
|
| Biomarkers, Tumor | 2 | 2011 | 1547 | 0.230 |
Why?
|
| Diagnosis, Differential | 9 | 2013 | 1607 | 0.230 |
Why?
|
| Fabry Disease | 1 | 2004 | 6 | 0.230 |
Why?
|
| Creatinine | 7 | 2014 | 295 | 0.220 |
Why?
|
| Eosinophils | 2 | 2021 | 195 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 153 | 0.220 |
Why?
|
| Child, Preschool | 8 | 2016 | 3764 | 0.210 |
Why?
|
| HIV Infections | 1 | 2012 | 857 | 0.210 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 1708 | 0.210 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2000 | 10 | 0.210 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 476 | 0.200 |
Why?
|
| Cell Nucleus | 2 | 2011 | 603 | 0.200 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2011 | 111 | 0.200 |
Why?
|
| Disease Progression | 6 | 2018 | 1483 | 0.200 |
Why?
|
| Sex Factors | 2 | 2018 | 1074 | 0.200 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2021 | 25 | 0.190 |
Why?
|
| Young Adult | 6 | 2018 | 6409 | 0.190 |
Why?
|
| Isoxazoles | 3 | 2006 | 77 | 0.190 |
Why?
|
| Eosinophilic Granuloma | 1 | 2021 | 11 | 0.180 |
Why?
|
| Histiocytes | 1 | 2021 | 23 | 0.180 |
Why?
|
| Jaw Diseases | 1 | 2000 | 8 | 0.180 |
Why?
|
| Facial Pain | 1 | 2000 | 11 | 0.180 |
Why?
|
| Acute Disease | 4 | 2010 | 854 | 0.180 |
Why?
|
| Viremia | 2 | 2017 | 49 | 0.180 |
Why?
|
| Chicago | 4 | 2015 | 1438 | 0.180 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2000 | 95 | 0.180 |
Why?
|
| Biopsy, Needle | 3 | 2018 | 233 | 0.170 |
Why?
|
| Immunoglobulin A | 1 | 2000 | 84 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2018 | 2334 | 0.170 |
Why?
|
| Giant Cells | 1 | 1999 | 19 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 3689 | 0.170 |
Why?
|
| Endothelium, Vascular | 3 | 2012 | 437 | 0.170 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1999 | 63 | 0.160 |
Why?
|
| Postoperative Complications | 5 | 2006 | 2336 | 0.160 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 97 | 0.160 |
Why?
|
| Necrosis | 2 | 2014 | 211 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2016 | 30 | 0.160 |
Why?
|
| Cyclophosphamide | 2 | 2015 | 303 | 0.160 |
Why?
|
| Stromal Cells | 1 | 1999 | 151 | 0.160 |
Why?
|
| Nephrectomy | 3 | 2011 | 291 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2018 | 63 | 0.150 |
Why?
|
| Serum Amyloid A Protein | 1 | 2018 | 25 | 0.150 |
Why?
|
| Antiviral Agents | 4 | 2008 | 485 | 0.150 |
Why?
|
| Immunocompromised Host | 2 | 2011 | 142 | 0.150 |
Why?
|
| Dermatitis | 2 | 2021 | 34 | 0.150 |
Why?
|
| Inflammation | 3 | 2021 | 988 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2015 | 276 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2019 | 232 | 0.150 |
Why?
|
| Tacrolimus | 3 | 2012 | 371 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 4 | 2000 | 286 | 0.140 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 63 | 0.140 |
Why?
|
| Transplantation, Heterologous | 4 | 2000 | 368 | 0.140 |
Why?
|
| Case-Control Studies | 4 | 2016 | 1872 | 0.140 |
Why?
|
| Survival Rate | 2 | 2011 | 1899 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 360 | 0.140 |
Why?
|
| Learning | 1 | 2019 | 287 | 0.130 |
Why?
|
| Antigens, CD | 3 | 2014 | 467 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2017 | 265 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 2 | 2015 | 279 | 0.130 |
Why?
|
| Skin Diseases, Genetic | 1 | 2016 | 4 | 0.130 |
Why?
|
| Contracture | 1 | 2016 | 19 | 0.130 |
Why?
|
| Receptors, Cell Surface | 2 | 2014 | 289 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1085 | 0.130 |
Why?
|
| Kidney Medulla | 2 | 2014 | 80 | 0.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 23 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 283 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 104 | 0.130 |
Why?
|
| Macrophage Activation | 2 | 2014 | 49 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 320 | 0.130 |
Why?
|
| Glucocorticoids | 3 | 2012 | 359 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 1999 | 693 | 0.120 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 32 | 0.120 |
Why?
|
| Curriculum | 1 | 2019 | 574 | 0.120 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 29 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 136 | 0.120 |
Why?
|
| Rituximab | 1 | 2015 | 120 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2018 | 8362 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 1997 | 279 | 0.120 |
Why?
|
| Risk Factors | 3 | 2016 | 5576 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2781 | 0.120 |
Why?
|
| Elementary Particles | 1 | 2014 | 11 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1741 | 0.110 |
Why?
|
| Vasculitis | 3 | 2021 | 40 | 0.110 |
Why?
|
| Quantum Theory | 1 | 2014 | 32 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2019 | 795 | 0.110 |
Why?
|
| Infant | 5 | 2016 | 3183 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 4345 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2014 | 255 | 0.110 |
Why?
|
| Thrombosis | 2 | 2014 | 312 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2009 | 525 | 0.110 |
Why?
|
| Hepatorenal Syndrome | 1 | 2013 | 8 | 0.110 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2013 | 22 | 0.110 |
Why?
|
| Melanoma | 2 | 2011 | 473 | 0.110 |
Why?
|
| Vulvar Diseases | 1 | 2012 | 8 | 0.110 |
Why?
|
| Cyclosporine | 5 | 2008 | 239 | 0.110 |
Why?
|
| Fluocinolone Acetonide | 1 | 2012 | 8 | 0.110 |
Why?
|
| Bile | 1 | 2013 | 60 | 0.110 |
Why?
|
| Bilirubin | 1 | 2013 | 131 | 0.100 |
Why?
|
| Nipples | 1 | 2012 | 37 | 0.100 |
Why?
|
| Axilla | 1 | 2012 | 103 | 0.100 |
Why?
|
| Apoptosis | 3 | 2000 | 1721 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 145 | 0.100 |
Why?
|
| Phaeohyphomycosis | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lichenoid Eruptions | 1 | 2011 | 3 | 0.100 |
Why?
|
| Costa Rica | 1 | 2011 | 15 | 0.100 |
Why?
|
| Voriconazole | 1 | 2011 | 18 | 0.100 |
Why?
|
| Photosensitivity Disorders | 1 | 2011 | 15 | 0.100 |
Why?
|
| Purpura | 1 | 2011 | 10 | 0.100 |
Why?
|
| Itraconazole | 1 | 2011 | 11 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 2 | 2003 | 303 | 0.100 |
Why?
|
| Melanins | 1 | 2011 | 23 | 0.100 |
Why?
|
| Vitiligo | 1 | 2011 | 17 | 0.100 |
Why?
|
| Amphotericin B | 1 | 2011 | 36 | 0.100 |
Why?
|
| Erythema | 1 | 2011 | 29 | 0.100 |
Why?
|
| Soil Microbiology | 1 | 2011 | 25 | 0.100 |
Why?
|
| Microcirculation | 1 | 2012 | 105 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 229 | 0.100 |
Why?
|
| Proteins | 1 | 1997 | 788 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 81 | 0.090 |
Why?
|
| Mitosis | 1 | 2011 | 152 | 0.090 |
Why?
|
| Leg | 1 | 2011 | 140 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2014 | 493 | 0.090 |
Why?
|
| Antibodies, Antinuclear | 2 | 2012 | 85 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2014 | 511 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 615 | 0.090 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2013 | 61 | 0.090 |
Why?
|
| Triazoles | 1 | 2011 | 107 | 0.090 |
Why?
|
| England | 1 | 2010 | 38 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2011 | 123 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 172 | 0.090 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2010 | 40 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 1997 | 1229 | 0.090 |
Why?
|
| Arterioles | 2 | 2008 | 22 | 0.090 |
Why?
|
| Pneumonia | 1 | 2011 | 184 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2519 | 0.080 |
Why?
|
| Keratosis, Seborrheic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Electron Probe Microanalysis | 1 | 2009 | 8 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 1096 | 0.080 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2008 | 5 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 1170 | 0.080 |
Why?
|
| Lichen Planus | 1 | 2008 | 10 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 371 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 679 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2009 | 102 | 0.080 |
Why?
|
| Exercise | 1 | 2011 | 328 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2008 | 14 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2008 | 87 | 0.070 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 44 | 0.070 |
Why?
|
| Phenotype | 1 | 2014 | 2462 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2012 | 75 | 0.070 |
Why?
|
| RNA, Viral | 3 | 2012 | 320 | 0.070 |
Why?
|
| Thymus Gland | 3 | 1997 | 197 | 0.070 |
Why?
|
| Pathology, Surgical | 1 | 2007 | 12 | 0.070 |
Why?
|
| Prognosis | 4 | 2016 | 3805 | 0.070 |
Why?
|
| Immune Tolerance | 3 | 1999 | 344 | 0.070 |
Why?
|
| Hepatitis C | 3 | 2012 | 174 | 0.070 |
Why?
|
| Hidradenitis | 1 | 2006 | 2 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2007 | 98 | 0.070 |
Why?
|
| Cellulitis | 1 | 2006 | 19 | 0.070 |
Why?
|
| Bowman Capsule | 1 | 2006 | 6 | 0.070 |
Why?
|
| Comorbidity | 1 | 2010 | 955 | 0.070 |
Why?
|
| Neprilysin | 1 | 2006 | 41 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 324 | 0.070 |
Why?
|
| Mucin-1 | 1 | 2006 | 44 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 160 | 0.070 |
Why?
|
| Cytarabine | 1 | 2006 | 220 | 0.070 |
Why?
|
| Actins | 2 | 1999 | 469 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1997 | 202 | 0.060 |
Why?
|
| Psoriasis | 1 | 2008 | 245 | 0.060 |
Why?
|
| Nephrocalcinosis | 1 | 2005 | 9 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1356 | 0.060 |
Why?
|
| Recurrence | 1 | 2008 | 1162 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 194 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2005 | 50 | 0.060 |
Why?
|
| Fibrosis | 1 | 2005 | 238 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2010 | 2501 | 0.060 |
Why?
|
| alpha-Galactosidase | 1 | 2004 | 5 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2007 | 406 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 1869 | 0.050 |
Why?
|
| Nephritis | 1 | 2003 | 17 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2009 | 744 | 0.050 |
Why?
|
| Point Mutation | 1 | 2004 | 246 | 0.050 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 72 | 0.050 |
Why?
|
| Organophosphonates | 1 | 2003 | 52 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 161 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 54 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 264 | 0.050 |
Why?
|
| Swine | 6 | 2000 | 593 | 0.050 |
Why?
|
| Rats | 3 | 2005 | 4057 | 0.050 |
Why?
|
| Antigens, CD20 | 2 | 2012 | 35 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 2013 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 498 | 0.050 |
Why?
|
| Cytosine | 1 | 2003 | 130 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2006 | 285 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2005 | 343 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2021 | 10 | 0.050 |
Why?
|
| Pemphigoid, Bullous | 1 | 2021 | 12 | 0.050 |
Why?
|
| Muscle, Smooth | 2 | 2000 | 355 | 0.050 |
Why?
|
| Periapical Diseases | 1 | 2000 | 2 | 0.050 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2000 | 10 | 0.050 |
Why?
|
| Periodontal Diseases | 1 | 2000 | 9 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2000 | 55 | 0.040 |
Why?
|
| Cell Count | 1 | 2001 | 200 | 0.040 |
Why?
|
| Cell Movement | 2 | 2010 | 791 | 0.040 |
Why?
|
| Ligaments | 1 | 2000 | 34 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 2000 | 40 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 111 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 55 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 313 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2001 | 120 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 914 | 0.040 |
Why?
|
| Cadaver | 1 | 2000 | 186 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2006 | 801 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 332 | 0.040 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2000 | 61 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2001 | 177 | 0.040 |
Why?
|
| Keratins | 1 | 1999 | 63 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 2019 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 198 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 923 | 0.040 |
Why?
|
| Swine, Miniature | 4 | 2000 | 50 | 0.040 |
Why?
|
| Transplantation Tolerance | 1 | 2000 | 138 | 0.040 |
Why?
|
| Macaca fascicularis | 4 | 2000 | 109 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 1997 | 694 | 0.040 |
Why?
|
| Postoperative Period | 1 | 1999 | 301 | 0.040 |
Why?
|
| Antibodies | 2 | 1997 | 353 | 0.040 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 1997 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1987 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2401 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 511 | 0.040 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 1997 | 6 | 0.040 |
Why?
|
| Living Donors | 1 | 2000 | 339 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 1997 | 141 | 0.040 |
Why?
|
| Plasma | 1 | 2017 | 51 | 0.040 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 1997 | 9 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2017 | 47 | 0.040 |
Why?
|
| Thymectomy | 1 | 1997 | 31 | 0.030 |
Why?
|
| Phenanthridines | 1 | 1996 | 24 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 1997 | 115 | 0.030 |
Why?
|
| Incidence | 2 | 1998 | 1593 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 1997 | 82 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1997 | 167 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 1996 | 53 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1996 | 48 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 1998 | 211 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 1259 | 0.030 |
Why?
|
| CD3 Complex | 2 | 2012 | 135 | 0.030 |
Why?
|
| Triazines | 1 | 1996 | 54 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 207 | 0.030 |
Why?
|
| Crotonates | 2 | 2006 | 12 | 0.030 |
Why?
|
| Toluidines | 2 | 2006 | 18 | 0.030 |
Why?
|
| Hydroxybutyrates | 2 | 2006 | 27 | 0.030 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1997 | 243 | 0.030 |
Why?
|
| Aniline Compounds | 2 | 2006 | 59 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 165 | 0.030 |
Why?
|
| Urine | 2 | 2006 | 94 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 319 | 0.030 |
Why?
|
| Animals | 12 | 2005 | 27606 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 160 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 316 | 0.030 |
Why?
|
| Nitriles | 2 | 2006 | 156 | 0.030 |
Why?
|
| DNA | 1 | 2001 | 1313 | 0.030 |
Why?
|
| Papio | 3 | 2000 | 82 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 376 | 0.030 |
Why?
|
| Ischemia | 1 | 1996 | 254 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 569 | 0.030 |
Why?
|
| Mesons | 1 | 2014 | 9 | 0.030 |
Why?
|
| Electrons | 1 | 2014 | 50 | 0.030 |
Why?
|
| Jaundice | 1 | 2013 | 14 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 75 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 132 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 124 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 125 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2012 | 224 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.030 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2012 | 4 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 46 | 0.020 |
Why?
|
| Adiponectin | 1 | 2012 | 20 | 0.020 |
Why?
|
| Acitretin | 1 | 2011 | 4 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 18 | 0.020 |
Why?
|
| Yoga | 1 | 2011 | 5 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 9 | 0.020 |
Why?
|
| Eczema | 1 | 2011 | 7 | 0.020 |
Why?
|
| Lymphocytes | 2 | 2008 | 470 | 0.020 |
Why?
|
| Captopril | 1 | 1991 | 22 | 0.020 |
Why?
|
| Ultraviolet Therapy | 1 | 2011 | 16 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2011 | 16 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 67 | 0.020 |
Why?
|
| Running | 1 | 2011 | 26 | 0.020 |
Why?
|
| Silver Staining | 1 | 2011 | 6 | 0.020 |
Why?
|
| Veins | 1 | 2011 | 95 | 0.020 |
Why?
|
| Arm | 1 | 2011 | 99 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 73 | 0.020 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2010 | 20 | 0.020 |
Why?
|
| Bacteremia | 1 | 2011 | 103 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 215 | 0.020 |
Why?
|
| Germinal Center | 1 | 2010 | 55 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1997 | 1178 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2011 | 203 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 842 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 167 | 0.020 |
Why?
|
| Ointments | 1 | 2009 | 12 | 0.020 |
Why?
|
| Skin Care | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cosmetics | 1 | 2009 | 7 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 1182 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 161 | 0.020 |
Why?
|
| Porokeratosis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Betamethasone | 1 | 2008 | 5 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 809 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 38 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 277 | 0.020 |
Why?
|
| Pruritus | 1 | 2008 | 29 | 0.020 |
Why?
|
| Antibodies, Heterophile | 2 | 1999 | 20 | 0.020 |
Why?
|
| Alopecia | 1 | 2008 | 34 | 0.020 |
Why?
|
| Guanidines | 2 | 1999 | 31 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 111 | 0.020 |
Why?
|
| Peroxidase | 2 | 1999 | 51 | 0.020 |
Why?
|
| Epidermis | 1 | 2008 | 102 | 0.020 |
Why?
|
| Ureter | 1 | 2009 | 95 | 0.020 |
Why?
|
| Antibody Formation | 2 | 2000 | 172 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2008 | 214 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 293 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 741 | 0.020 |
Why?
|
| Reoperation | 2 | 2002 | 610 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2007 | 87 | 0.020 |
Why?
|
| Idarubicin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2067 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2329 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2007 | 279 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 1010 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 792 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 361 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3026 | 0.020 |
Why?
|
| Blood | 1 | 2006 | 69 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 347 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1999 | 1240 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 1750 | 0.020 |
Why?
|
| Urinary Calculi | 1 | 2005 | 46 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1997 | 472 | 0.010 |
Why?
|
| Urothelium | 1 | 2005 | 62 | 0.010 |
Why?
|
| Ileum | 1 | 2005 | 168 | 0.010 |
Why?
|
| Virus Replication | 1 | 2006 | 326 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 1999 | 1397 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 146 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1999 | 1227 | 0.010 |
Why?
|
| Epithelioid Cells | 1 | 2000 | 13 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2891 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1054 | 0.010 |
Why?
|
| Natriuresis | 1 | 1999 | 29 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2667 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1999 | 184 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 374 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 241 | 0.010 |
Why?
|
| Nevus, Intradermal | 1 | 1997 | 5 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1997 | 73 | 0.010 |
Why?
|
| Nephrosis, Lipoid | 1 | 1997 | 6 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1997 | 19 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 12 | 0.010 |
Why?
|
| Nevus | 1 | 1997 | 16 | 0.010 |
Why?
|
| Abatacept | 1 | 1997 | 86 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 566 | 0.010 |
Why?
|
| Hemoperfusion | 1 | 1997 | 5 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1997 | 140 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 93 | 0.010 |
Why?
|
| Age Distribution | 1 | 1997 | 198 | 0.010 |
Why?
|
| Morbidity | 1 | 1997 | 151 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 599 | 0.010 |
Why?
|
| Haplorhini | 1 | 1997 | 81 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1997 | 67 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1997 | 70 | 0.010 |
Why?
|
| Splenectomy | 1 | 1997 | 82 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 67 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 66 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1997 | 67 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 137 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1997 | 191 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 164 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1997 | 121 | 0.010 |
Why?
|
| Reperfusion | 1 | 1996 | 32 | 0.010 |
Why?
|
| Hepacivirus | 1 | 1997 | 131 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1997 | 179 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2003 | 2893 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 565 | 0.010 |
Why?
|
| Mice | 2 | 1999 | 11898 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1997 | 449 | 0.010 |
Why?
|
| Gene Expression | 1 | 1999 | 1312 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1996 | 671 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 1998 | 451 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 1996 | 342 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1996 | 982 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 756 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1999 | 2029 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 1929 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1991 | 137 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1991 | 878 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 2324 | 0.000 |
Why?
|